Compare TYGO & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYGO | SENS |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.0M | 301.2M |
| IPO Year | 2021 | 2014 |
| Metric | TYGO | SENS |
|---|---|---|
| Price | $2.93 | $7.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $18.38 |
| AVG Volume (30 Days) | ★ 618.9K | 518.3K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.12 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,536,000.00 | $16,389,000.00 |
| Revenue This Year | $30.78 | $74.15 |
| Revenue Next Year | $21.68 | $58.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.68 | 19.85 |
| 52 Week Low | $1.13 | $0.41 |
| 52 Week High | $5.33 | $8.75 |
| Indicator | TYGO | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 27.65 | 63.69 |
| Support Level | $1.45 | $7.35 |
| Resistance Level | $2.95 | $7.45 |
| Average True Range (ATR) | 0.26 | 0.46 |
| MACD | -0.10 | 0.11 |
| Stochastic Oscillator | 6.38 | 79.65 |
Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.